Company intelligence / Profile preview
SafeRx Pharmaceuticals
- Ownership
- Private
- Employees
- ~3
- Development stage
- Preclinical
Overview
SafeRx Pharmaceuticals is developing a patented platform of Alcohol Resistant Opioids (AROs), fixed-dose combinations of approved opioids with disulfiram. The goal is to prevent fatal overdoses caused by concurrent opioid and alcohol use—a factor in nearly one-quarter of prescription opioid deaths. The company expects its first ARO product to reach FDA approval within three years on a modest budget using the expedited regulatory pathway.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecules (fixed-dose opioid and disulfiram combinations)Combination products (opioid + alcohol deterrent)
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on SafeRx Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SafeRx Pharmaceuticals.